Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.8K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.8K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

755
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
755
5-Number Summary01:04

5-Number Summary

5.5K
In a dataset, the 5-number summary includes the minimum data value, the data value of the first quartile, the median data value or data value of the second quartile, the data value of the third quartile, and the maximum data value. These 5 data values can be visualized as a box and whisker plot.
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
5.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

618
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
618
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials.

Pulmonary therapy·2026
Same author

Authors' response.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Appropriate Use of Single Inhaled Triple Therapy in Uncontrolled Asthma: A Multinational Modified Delphi Consensus.

Journal of asthma and allergy·2026
Same author

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

Lancet (London, England)·2026
Same author

Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.

The World Allergy Organization journal·2026
Same author

Impact of Sex on Prediction of Asthma Attacks by Clinical Risk Factors and Type 2 Biomarkers.

Chest·2026

Related Experiment Video

Updated: Jan 23, 2026

Immunohistochemical Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine in Developing and Postmitotic Mouse Retina
07:50

Immunohistochemical Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine in Developing and Postmitotic Mouse Retina

Published on: August 29, 2018

9.4K

Targeting IL-5 in COPD.

Dharani K Narendra1, Nicola A Hanania1

  • 1Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA.

International Journal of Chronic Obstructive Pulmonary Disease
|June 14, 2019
PubMed
Summary
This summary is machine-generated.

Chronic obstructive pulmonary disease (COPD) patients may benefit from new treatments targeting eosinophilic inflammation. Blocking interleukin-5 (IL-5) shows promise for specific COPD types, offering a personalized therapy approach.

Keywords:
COPDIL-5airway inflammationbenralizumabeosinophilsmepolizumab

More Related Videos

Selective Capture of 5-hydroxymethylcytosine from Genomic DNA
06:26

Selective Capture of 5-hydroxymethylcytosine from Genomic DNA

Published on: October 5, 2012

12.3K
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

7.1K

Related Experiment Videos

Last Updated: Jan 23, 2026

Immunohistochemical Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine in Developing and Postmitotic Mouse Retina
07:50

Immunohistochemical Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine in Developing and Postmitotic Mouse Retina

Published on: August 29, 2018

9.4K
Selective Capture of 5-hydroxymethylcytosine from Genomic DNA
06:26

Selective Capture of 5-hydroxymethylcytosine from Genomic DNA

Published on: October 5, 2012

12.3K
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

7.1K

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Pharmacology

Background:

  • Standard treatments for chronic obstructive pulmonary disease (COPD) do not prevent exacerbations in many patients.
  • Understanding molecular mechanisms of airway inflammation, obstruction, remodeling, and lung destruction is key for novel COPD therapies.
  • COPD is often linked to neutrophilic inflammation but can also involve eosinophilic inflammation during stable states and exacerbations.

Purpose of the Study:

  • To review the current understanding of eosinophilic inflammation in COPD.
  • To examine the rationale for using interleukin-5 (IL-5) targeting agents in COPD treatment.
  • To explore the potential of personalized therapy based on COPD phenotypes and endotypes.

Main Methods:

  • Literature review of studies on COPD, eosinophilic inflammation, and IL-5 targeting agents.
  • Analysis of current research on COPD phenotypes and endotypes.
  • Examination of data from clinical trials of biologic treatments for COPD.

Main Results:

  • Eosinophilic inflammation plays a role in certain COPD phenotypes, both in stable disease and during exacerbations.
  • Targeting eosinophilic inflammation has proven effective in severe eosinophilic asthma.
  • Biologic agents blocking IL-5 or its receptor are in advanced development for COPD.

Conclusions:

  • Targeting eosinophilic inflammation, particularly with IL-5 blocking agents, represents a promising avenue for personalized COPD therapy.
  • Further research into COPD endotypes is crucial for identifying patients who will benefit most from targeted treatments.
  • Personalized medicine approaches hold the potential to improve outcomes for patients with COPD experiencing exacerbations.